Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOLYTE E IN PLASTIC CONTAINER vs CARBAGLU
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ISOLYTE E is an intravenous electrolyte replacement solution that provides water, electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, and gluconate), and bicarbonate precursors to correct fluid and electrolyte imbalances. The acetate and gluconate ions are metabolized to bicarbonate in the liver, providing an alkaline buffer.
Carbaglu (carbonic anhydrase inhibitor) reduces intraocular pressure by inhibiting carbonic anhydrase in the ciliary processes, thereby decreasing aqueous humor secretion.
Maintenance of fluid and electrolyte balance in patients unable to take oral intake,Correction of metabolic acidosis when bicarbonate is contraindicated or not available,Replacement of electrolytes in hypokalemia, hyponatremia, hypomagnesemia, and hypocalcemia
Adjunctive treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma
Intravenous infusion; rate and volume determined by individual patient requirements for fluid and electrolyte replacement. Typical adult dose: 500-1000 m L as a single infusion, administered at a rate of 5-10 m L/min.
100 mg/kg (up to 200 mg/kg) intravenous infusion over 90 minutes, followed by 100 mg/kg/day continuous intravenous infusion; maintenance: 100 mg/kg/day oral divided into 2-4 doses, not to exceed 20 g/day.
Not applicable as a single agent; components have variable half-lives (e.g., sodium and chloride distribute rapidly with an elimination half-life of 2-4 hours depending on renal function). In renal impairment, half-life may be prolonged.
Terminal half-life approximately 5.8 hours in adults; prolonged in hepatic impairment (up to 10 hours).
Acetate and gluconate are metabolized in the liver via the tricarboxylic acid cycle to bicarbonate; electrolytes are distributed in body fluids and excreted renally.
Metabolized via hepatic glucuronidation and renal excretion; not extensively metabolized by CYP450 enzymes.
Renal: >95% of administered electrolytes and water are excreted unchanged by the kidneys, primarily as urine. Biliary/fecal: <5% eliminated via feces, mainly unabsorbed components.
Primarily renal excretion (97% unchanged) with minimal biliary/fecal elimination (<3%).
Minimal to none: electrolytes like sodium, potassium, chloride, and bicarbonate are not protein-bound (<1%). Magnesium and calcium may have 30-50% binding to albumin, but overall negligible in solution.
Negligible (<1% bound to albumin or other plasma proteins).
Distributes primarily into extracellular fluid (ECF) with Vd approximately 0.2 L/kg for sodium and chloride; calcium and magnesium distribute into a larger volume (0.5-0.6 L/kg) due to intracellular uptake.
Vd approximately 0.3 L/kg, indicating distribution primarily in extracellular fluid.
Intravenous: 100% (complete systemic availability). Not administered orally or by other routes for systemic effect.
Oral bioavailability approximately 30% (range 20-40%) due to first-pass metabolism; IV bioavailability 100%.
Contraindicated in patients with severe renal impairment (GFR < 30 m L/min) due to risk of hyperkalemia. For GFR 30-50 m L/min, reduce infusion rate by 50% and monitor serum potassium closely. No adjustment needed for GFR > 50 m L/min.
No specific dose adjustment is provided in the manufacturer's labeling; use with caution in renal impairment. GFR <30 m L/min: consider alternative therapy.
Child-Pugh Class A: no adjustment. Class B: reduce infusion rate by 25% and monitor serum potassium. Class C: use with caution; consider alternative solutions due to risk of electrolyte imbalance.
No specific adjustment is recommended for hepatic impairment per labeling; monitor transaminases.
Weight-based dosing: 20-30 m L/kg as a single intravenous infusion, administered at a rate not exceeding 5 m L/kg/hour. Maximum total volume: 1000 m L. Adjust based on clinical status and serum electrolytes.
Loading dose: 100 mg/kg (up to 200 mg/kg) IV over 90 minutes; continuous infusion: 100-200 mg/kg/day IV or oral divided q4-6h; maximum 20 g/day.
Elderly patients may require reduced infusion rates (2-5 m L/min) due to decreased renal function and higher risk of fluid overload. Monitor serum potassium and renal function closely.
No specific adjustments; use lowest effective dose and monitor renal function given age-related decline.
None
Sulfonamide derivative; may cause serious, potentially fatal reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and agranulocytosis. Discontinue at first sign of rash or other hypersensitivity.
Monitor serum electrolytes, fluid balance, and renal function regularly. Use with caution in patients with heart failure, renal impairment, or conditions predisposing to hypervolemia. Avoid rapid infusion; extravasation may cause tissue damage. Contains aluminum, which may accumulate in renal impairment.
Sulfonamide hypersensitivity: may cause serious skin reactions and blood dyscrasias; discontinue if rash or signs of hypersensitivity occur.,May cause metabolic acidosis; use caution in patients with respiratory acidosis, diabetes, or electrolyte disturbances.,May cause drowsiness, dizziness, or blurred vision; caution when driving or operating machinery.
Hyperkalemia, hypernatremia, hypercalcemia, hypermagnesemia, severe metabolic alkalosis, severe renal failure with oliguria or anuria, and patients with a known hypersensitivity to any component.
Hypersensitivity to carbonic anhydrase inhibitors or sulfonamides,Severe renal impairment (Cr Cl <10 m L/min),Adrenocortical insufficiency (Addison's disease),Severe hepatic insufficiency
No direct food interactions; however, patients should avoid high-potassium foods (e.g., bananas, oranges, tomatoes) if hyperkalemia is a concern. Monitor dietary sodium and fluid intake as per clinical status.
No specific food interactions; however, patients with urea cycle disorders often require protein restriction. For Carbaglu, avoid acidic beverages (e.g., fruit juice) as they may degrade the drug. Administer with water only.
ISOLYTE E in plastic container is a balanced electrolyte solution without known teratogenic risk. No fetal harm has been documented in any trimester; however, excessive or rapid administration may cause maternal fluid and electrolyte disturbances that can indirectly affect the fetus. Use with caution in the setting of impaired uteroplacental perfusion.
First trimester: Limited human data; animal studies show no increased risk of malformations. Second/third trimester: No known fetal harm; can be used for NAGS deficiency.
ISOLYTE E is compatible with breastfeeding. Electrolytes are normally present in breast milk; exogenous administration does not significantly alter infant exposure. M/P ratio not applicable as drug is not a xenobiotic.
No human data; M/P ratio unknown. Use with caution.
No dose adjustment is required for pregnancy. However, pregnant patients may have increased plasma volume and altered renal function; infusion rates should be individualized based on clinical status and serum electrolyte monitoring. Rapid correction of electrolyte imbalances should be avoided to prevent fetal osmotic shifts.
No specific dose adjustments required; monitor ammonia levels to guide therapy.
ISOLYTE E is a balanced electrolyte solution with 5% dextrose, used for maintenance fluid therapy. Monitor serum potassium closely in renal impairment; contains 20 m Eq/L potassium. Caution in patients with hyperkalemia, renal failure, or metabolic alkalosis. Do not administer simultaneously with blood products due to risk of hemolysis. Observe for signs of fluid overload in patients with heart failure.
Carbaglu (carglumic acid) is a structural analog of N-acetylglutamate (NAG) and acts as a replacement therapy for N-acetylglutamate synthase (NAGS) deficiency. It is also used for hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA). Monitor ammonia levels closely; therapeutic goal is normalization within 24 hours. Administer via oral or nasogastric tube; dissolve tablets in water and administer immediately. Do not mix with acidic fluids (e.g., fruit juice) as stability may be affected. May cause headaches, vomiting, and fever. For NAGS deficiency, lifelong treatment is required. For PA/MMA, use is acute and short-term. Not effective for other urea cycle disorders.
This solution is used to replace fluids and electrolytes and provide calories. Tell your doctor if you have kidney problems, heart disease, or are on a low-potassium diet. Report any swelling, shortness of breath, or irregular heartbeat. Do not take over-the-counter potassium supplements without consulting your doctor.
Take Carbaglu exactly as prescribed; do not skip doses.,Dissolve the tablet(s) in a small amount of water (2.5 m L per tablet) and drink immediately. Do not mix with juice or other acidic beverages.,If using a nasogastric tube, ensure the solution is given right after preparation.,Monitor for signs of high ammonia (e.g., lethargy, vomiting, irritability) and report to doctor immediately.,Keep all appointments for blood tests to check ammonia levels.,Store tablets at room temperature (20-25°C), away from moisture and light.,Inform your doctor of all other medications, especially valproic acid (may decrease effectiveness).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOLYTE E IN PLASTIC CONTAINER vs CARBAGLU, answered by our medical review team.
ISOLYTE E IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by ISOLYTE E is an intravenous electrolyte replacement solution that provides water, electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, and gluconate), and bicarbonate precursors to correct fluid and electrolyte imbalances. The acetate and gluconate ions are metabolized to bicarbonate in the liver, providing an alkaline buffer.. CARBAGLU is a Ammonia Detoxicant that works by Carbaglu (carbonic anhydrase inhibitor) reduces intraocular pressure by inhibiting carbonic anhydrase in the ciliary processes, thereby decreasing aqueous humor secretion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOLYTE E IN PLASTIC CONTAINER and CARBAGLU depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOLYTE E IN PLASTIC CONTAINER is: Intravenous infusion; rate and volume determined by individual patient requirements for fluid and electrolyte replacement. Typical adult dose: 500-1000 m L as a single infusion, administered at a rate of 5-10 m L/min.. The standard adult dose of CARBAGLU is: 100 mg/kg (up to 200 mg/kg) intravenous infusion over 90 minutes, followed by 100 mg/kg/day continuous intravenous infusion; maintenance: 100 mg/kg/day oral divided into 2-4 doses, not to exceed 20 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOLYTE E IN PLASTIC CONTAINER and CARBAGLU in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOLYTE E IN PLASTIC CONTAINER is classified as Category C. ISOLYTE E in plastic container is a balanced electrolyte solution without known teratogenic risk. No fetal harm has been documented in any trimester; however, excessive or rapid ad. CARBAGLU is classified as Category C. First trimester: Limited human data; animal studies show no increased risk of malformations. Second/third trimester: No known fetal harm; can be used for NAGS deficiency.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.